TABLE III.
Transplant platform characteristics, by donor type
| Total HCTs (n = 66) | MSD HCTs (n = 7) | 8/8 MUD HCTs (n = 36) | Haplo HCTs (n = 15) | Other HCTs (n = 8) | |
|---|---|---|---|---|---|
| Conditioning intensity | |||||
| MAC | 24 (36) | 7 (100) | 11 (31) | 5 (33) | 1 (13) |
| RT-MAC | 6 (9) | 0 | 6 (17) | 0 | 0 |
| RIC | 35 (53) | 0 | 19 (53) | 9 (60) | 7 (88) |
| Nonmyeloablative conditioning | 1 (2) | 0 | 0 | 1 (7) | 0 |
| Serotherapy use | 55 (83) | 5 (71) | 34 (84) | 11 (73) | 5 (63) |
| Antithymocyte globulin | 33 (50) | 4 (57) | 18 (50) | 8 (53) | 3 (38) |
| Rabbit | 29 (44) | 4 (57) | 15 (42) | 7 (47) | 3 (38) |
| Horse | 4 (6) | 0 | 3 (8) | 1 (7) | 0 |
| Alemtuzumab | 22 (33) | 1 (14) | 16 (44) | 3 (20) | 2 (25) |
| Proximal timing (administered day −8 or closer to HCT) | 15 (23) | 1 (14) | 12 (33) | 0 | 2 (25) |
| Intermediate timing (administered between days −16 and −9) | 7 (11) | 0 | 4 (11) | 3 (20) | 0 |
| Total body irradiation (total dose, 2–4 Gy) | 12 (18) | 0 | 6 (17) | 3 (20) | 3 (38) |
| GVHD prophylaxis | |||||
| Calcineurin inhibitor-based | 48 (73) | 7 (100) | 29 (81) | 5 (3) | 7 (88) |
| Posttransplantation cyclophosphamide-based | 13 (20) | 0 | 5 (14) | 8 (53) | 0 |
| Graft manipulation | 8 (13) | 0 | 4 (11) | 3 (20) | 1 (13) |
| α/b T-cell/CD19+ depletion, with or without CD45RA− add-back | 6 (9) | 0 | 3 (8) | 2 (13) | 1 (13) |
| α/b T-cell depletion | 1 (2) | 0 | 0 | 1 (7) | 0 |
| CD34+ positive selection | 1 (2) | 0 | 1 (3) | 0 | 0 |
| No pharmacologic prophylaxis apart from serotherapy | 3 (5) | 0 | 0 | 2 (13) | 1 (13) |
| Other*/incomplete information | 2 (3) | 0 | 2 (6) | 0 | 0 |
Values are n or n (%).
*
In addition to rabbit antithymocyte globulin and graft manipulation, patient received abatacept and mycophenolate mofetil early post-HCT, followed by methotrexate.